FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Bowden Christopher (Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET (Street) CAMBRIDGE MA 02139							2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO] 3. Date of Earliest Transaction (Month/Day/Year) 08/29/2018 4. If Amendment, Date of Original Filed (Month/Day/Year)								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director					
(City)	(5		(Zip) ===== le I - N o	on-Deriv	vative	e Se	curit	ies Ac	guired	l, Di	sposed o	of, or Be	neficia	lly Owne	d					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					ction	2A Ex	2A. Deemed Execution Date,		3.		4. Securities Acquired (A)		d (A) or	5. Amor Securiti Benefic Owned	unt of ies ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
					(Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)			
Common stock			08/29/	29/2018				M ⁽¹⁾		300	A	\$35.1	6 1	1,224		D				
Common stock					/2018				S ⁽²⁾		300	D	\$80		924		D			
Common stock 08/30/2					/2018	018			M ⁽¹⁾		1,700	A	\$35.1	6 2	2,624		D			
Common stock 08/30/20					/2018	.018		S ⁽²⁾		1,700	D	\$80.03	0.03 ⁽³⁾ 924		D					
		7	able II								posed of converti			y Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Execution if any (Month/E	ned	4. Transa Code (8)	ection	5. Number		6. Date Exerci Expiration Dat (Month/Day/Ye		isable and te	7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	. v (Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares							
Stock option (right to buy)	\$35.16	08/29/2018			M ⁽¹⁾			300	(4)		05/30/2024	Common stock	300	\$0.00	92,700)	D			
Stock option	\$35.16	08/30/2018			M ⁽¹⁾			1,700	(4)		05/30/2024	Common	1,700	\$0.00	91,000		D			

Explanation of Responses:

- 1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$80.00 to \$80.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 4. This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

(right to

buy)

/s/ William Cook, as Attorneyin-fact for Christopher Bowden

stock

08/31/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.